A B Stra C T B
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Cytokines MONTRÉAL 2008
Cytokines MONTRÉAL 2008 Translating Science into Health: Cytokines in Cancer, Infl ammation and Infectious Diseases 7th Joint Conference of the International Cytokine Society and the International Society for Interferon and Cytokine Research Photo: Tourisme Montréal Photo: Tourisme October 12-16, 2008 Fairmont Queen Elizabeth Hotel Montreal Quebec CANADA Cytokines Montreal 2008 1 PROGRAM From cell separation to molecular analysis The Gold Standard in Cell Isolation • Separation of functional, cytokine-secreting cells • Virtually any cell type from any species • Superior viability, purity and recovery Cytokines and Growth Factors • New, broad portfolio: human - mouse - rat • Excellent purity and activity • Optimized for cell culture applications MACSmolecular Tools for Molecular Analysis • Tools for signal transduction • State of the art microRNA analysis • Comprehensive gene expression profiling Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. Miltenyi Biotec Inc. Phone 800 FOR MACS www.miltenyibiotec.com 12740 Earhart Avenue +1 530 888 8871 [email protected] Auburn CA 95602, USA Fax +1 530 888 8925 2 Cytokines Montreal 2008 ContentsWelcome to Montreal ..................................................................................... 4-5 Sponsors and Exhibitors ................................................................................... 6 Conference Venue ........................................................................................... -
Beyond Vaccines: Promising Therapeutics for COVID-19 and Emerging Viruses
Research Canada speaks to Dr. Eleanor Fish, a scientific advisor to Canada’s COVID- 19 Therapeutics Task Force Beyond Vaccines: Promising Therapeutics for COVID-19 and Emerging Viruses The federal government’s COVID-19 Therapeutics Task Force provides advice on the best and most promising treatments for COVID-19 procurement, whether these are still in development and merit support, including via applications to the federal Strategic Innovation Fund, or are existing medications. The Task Force also makes recommendations on therapies developed for a different use that may have an application to COVID-19. Dr. Eleanor Fish is among 11 science advisors to the Therapeutics Task Force. A Professor of Immunology at the University of Toronto and a Senior Scientist at University Health Network, she investigates the behaviour of cytokines, which play a role in cell-to-cell communication during the body’s immune response. In a recent Research Canada interview with Ms. Deborah Gordon-El- Bihbety, President and CEO, Dr. Fish talked about the critical place of therapeutics in the battle against COVID-19, and their important role in preparing for the diseases and epidemics to come. "Vaccines are a very important tool in our toolbox against COVID-19, but they are not a complete solution." - Dr. Eleanor Fish 1 RESEARCH CANADA: Canada’s vaccination campaign is under way, and we’ve been told that all Canadians who want a vaccine will have it by next fall. What role do therapeutics play, separate from vaccines, in the fight against COVID-19? DR. ELEANOR FISH: Vaccines are a very important tool in our toolbox against COVID-19, but they are not a complete solution. -
Advancing Tuberculosis Vaccines from Discovery to Clinical Development
Research Collection Review Article TBVAC2020: Advancing tuberculosis vaccines from discovery to clinical development Author(s): Kaufmann, Stefan H.E.; Dockrell, Hazel M.; Drager, Nick; Ho, Mei M.; McShane, Helen; Neyrolles, Olivier; Ottenhoff, Tom H.M.; Patel, Brij; Roordink, Danielle; Spertini, François; Stenger, Steffen; Thole, Jelle; Verreck, Frank A.W.; Williams, Ann; TBVAC2020 Consortium Publication Date: 2017-10-04 Permanent Link: https://doi.org/10.3929/ethz-b-000197748 Originally published in: Frontiers in Immunology 8, http://doi.org/10.3389/fimmu.2017.01203 Rights / License: Creative Commons Attribution 4.0 International This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library REVIEW published: 04 October 2017 doi: 10.3389/fimmu.2017.01203 TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development Stefan H. E. Kaufmann1*, Hazel M. Dockrell 2, Nick Drager 3, Mei Mei Ho4, Helen McShane5, Olivier Neyrolles 6, Tom H. M. Ottenhoff 7, Brij Patel 8, Danielle Roordink3, François Spertini 9, Steffen Stenger10, Jelle Thole3, Frank A. W. Verreck11, Ann Williams12 and TBVAC2020 Consortium 1 Department of Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, 2 Immunology and Infection Department, London School of Hygiene and Tropical Medicine, London, United Kingdom, 3 Tuberculosis Vaccine Initiative (TBVI), Lelystad, Netherlands, 4 Bacteriology Division, MHRA-NIBSC, Potters Bar, United Kingdom, -
PDF Hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/83292 Please be advised that this information was generated on 2017-12-06 and may be subject to change. De kunst van bruggen bouwen inaugurele rede door prof. dr. mihai g. netea inaugurele rede prof. dr. mihai g. netea In de afgelopen halve eeuw zijn we getuige geweest van een explosie in kennis over moleculaire biologie, cellu- laire fysiologie en genetica. Tegelijkertijd is er een steeds diepere kloof ontstaan tus- sen de onderzoeker en de klinisch specialist, en zijn de spectaculaire ontdekkin- gen gevolgd door een te- leurstellend gering aantal nieuwe geneesmiddelen. De uitdaging is om de bevin- dingen te vertalen naar de praktische klinische toe- passing. Volgens hoogleraar Experimentele interne genees- kunde Mihai Netea is het de taak van de translatione- le geneeskunde in het algemeen, en de experimentele interne geneeskunde in het bijzonder om een brug te bouwen tussen laboratorium en patiëntenzorg, met op die brug verkeer in beide richtingen. Hij richt zich enerzijds op de introductie van nieuwe geavanceerde technieken op het gebied van moleculaire biologie en celbiologie, en anderzijds op de versterking van trans- lationeel onderzoek tussen fundamentele wetenschap en klinisch onderzoek. Voor die versterking zijn inspanningen nodig van alle betrokkenen: nationale organisaties, universiteiten, onderzoeksgroepen en de onderzoekers zelf. Prof. dr. Mihai G. Netea (Cluj-Napoca, Roemenië, 1968) studeerde geneeskunde aan de Cluj-Napoca University, waar hij in 1993 afstudeerde. In 1998 pro- moveerde hij cum laude aan de Radboud Universiteit. -
ISICR Vol. 15.1
ISICR Officers President Eleanor Fish President-elect INTERNATIONAL SOCIETY FOR Leonidas Platanias INTERFERON AND CYTOKINE RESEARCH Secretary April 2008 Tom Hamilton Volume 15, No. 1 Treasurer Bob Friedman Executive Director A Message from the new ISICR Cliff Brownstein President, Eleanor Fish It is with gratitude and humility that I assume the Future ISICR Meetings responsibilities of incoming President of the ISICR. I am honored to have been elected by my peers and am fortunate to have in place a Board of 2008 Meeting Directors and Committee members that are as Joint ISICR/ICS committed to strengthening our Society as I am. In Montreal, Canada recent months, to ensure that our Society reflects Oct. 12-16 the scientific activities of junior investigators, as positions have www.cytokines2008.org become vacant on the various ISICR Committees, in consultation 2009 Meeting with the Committee Chairs I have made best efforts to invite the par- Joint ISICR/ICS/SLB ticipation of younger investigators who share our vision of a strong, Lisbon, Portugal international, collegial Society. I invite members to participate in your Society - just contact me to let me know of your interest. 2010 Meeting Joint ISICR/ICS Within recent years we have seen a revival of interest in the Chicago, Illinois pleiotropic activities of interferons, touching on many different bio- logical disciplines. Moreover, the role of cytokines and how they ISICR WWW Site inform us of biological processes in normal and diseased states is an www.ISICR.org ever expanding field. I would like to focus my tenure as President on a number of key areas: ISICR Business Office O Communication. -
Dec 08 News Vol 15 No 3 Final.Qxp
ISICR Officers President Eleanor Fish President-elect Leonidas Platanias Secretary Tom Hamilton December 2008 - Volume 15, No. 3 Treasurer Bob Friedman Executive Director One on one: An Interview with Cliff Brownstein Giorgio Trinchieri, Recipient of the 2008 Milstein Award Future ISICR Meetings Thomas Tan 2009 Meeting Giorgio Trinchieri received his medical degree Joint ISICR/ICS/SLB from the University of Torino, Italy, in 1973. He Lisbon, Portugal was a member of the Basel Institute for Immunology (Basel, Switzerland) and an investi- 2010 Meeting gator at the Swiss Institute for Experimental Joint ISICR/ICS Cancer Research (Epalanges sur Lausanne, Chicago, Illinois Switzerland). From 1979 to 1999 he was at Wistar Institute in Philadelphia and became Hilary Koprowski Professor and Chairman of the Immunology Program; he ISICR WWW Site was also Wistar Professor of Medicine at the University of www.ISICR.org Pennsylvania. He then served as director of the Schering Plough Laboratory for Immunological Research in Dardilly, France, and an ISICR Business Office NIH Fogarty Scholar at the Laboratory for Parasitic Diseases, [email protected] NIAID, before becoming director of the Cancer and Inflammation TEL: 301-634-7250 Program (CIP) and Chief of the Laboratory of Experimental FAX: 301-634-7420 Immunology at NCI in August 2006. As CIP director, he oversees the operations of two major NCI intramural laboratories, the Laboratory ISICR Newsletter Editors of Experimental Immunology and the Laboratory of Molecular Howard Young Immunoregulation. These two laboratories constitute the major [email protected] immunologic component of the inflammation and cancer initiative, Fax: 301-846-1673 which spans the NCI's campuses in Frederick and Bethesda and seeks Hannah Nguyen to partner NCI's expertise in inflammation and immunology with its cutting-edge cancer etiology and carcinogenesis program. -
Reassessing Twenty Years of Vaccine Development Against Tuberculosis Edited by : Ulrich E
REASSESSING TWENTY YEARS OF VACCINE DEVELOPMENT AGAINST TUBERCULOSIS EDITED BY : Ulrich E. Schaible and Stefan H. Kaufmann PUBLISHED IN : Frontiers in Immunology Frontiers Copyright Statement About Frontiers © Copyright 2007-2018 Frontiers Media SA. All rights reserved. Frontiers is more than just an open-access publisher of scholarly articles: it is a pioneering All content included on this site, approach to the world of academia, radically improving the way scholarly research such as text, graphics, logos, button icons, images, video/audio clips, is managed. The grand vision of Frontiers is a world where all people have an equal downloads, data compilations and software, is the property of or is opportunity to seek, share and generate knowledge. Frontiers provides immediate and licensed to Frontiers Media SA permanent online open access to all its publications, but this alone is not enough to (“Frontiers”) or its licensees and/or subcontractors. The copyright in the realize our grand goals. text of individual articles is the property of their respective authors, subject to a license granted to Frontiers. Frontiers Journal Series The compilation of articles constituting The Frontiers Journal Series is a multi-tier and interdisciplinary set of open-access, online this e-book, wherever published, as well as the compilation of all other journals, promising a paradigm shift from the current review, selection and dissemination content on this site, is the exclusive property of Frontiers. For the processes in academic publishing. All Frontiers journals are driven by researchers for conditions for downloading and researchers; therefore, they constitute a service to the scholarly community. At the same copying of e-books from Frontiers’ website, please see the Terms for time, the Frontiers Journal Series operates on a revolutionary invention, the tiered publishing Website Use. -
Neue Arbeitsgruppe Am LIMES-Institut: Infectious Deseases and Global Health Interview Mit Prof. Dr. Mihai Netea 12. Januar 2017
Neue Arbeitsgruppe am LIMES-Institut: Infectious deseases and global health Interview mit Prof. Dr. Mihai Netea 12. Januar 2017 Since January 2017, Prof. Dr. Mihai Netea has a new working group at the LIMES Institute. He will be em- ployed both at the University of Nijmegen and the University of Bonn. To get to know him a bit, we asked him a few questions: Welcome to the LIMES team. Please introduce your- self in a few sentences. I am an internist and infectious diseases specialist. I was born and did my medical studies in Cluj-Napoca, ning of building a research culture, but this has started Romania. After finishing the medical studies in 1993, I to change fast in the last couple of years. moved to Radboud University Nijmegen for the PhD and clinical specialization with the group of Prof. Dr. What inspired your decision to join the LIMES Insti- Jos van der Meer. After another year as a post-doc at tute in Bonn? the University of Colorado, Denver, in the lab of Prof. Charles Dinarello, I moved back to Nijmegen, where I have had a very fruitful collaboration with researchers I work as a Professor of Experimental Medicine since at LIMES for several years already. It was very stimula- 2008. ting to perform these collaborative projects together, and we have observed how nice our expertise is com- You are working on infectious diseases and global plementary. It was thus an organic process in which health. What is your key interest and why? we thought to improve this collaboration even further by joining the LIMES. -
Curriculum Vitae
Biodata: Professor Rabia Hussain ( email: [email protected]) EDUCATION 1966 B.Sc (Hon). Karachi University. Division 1 Position 1 (summa cum laude) Subjects: Microbiology, Biochemistry and Botany. (summa cum laude) 1967 M.Sc. Karachi University, Division 1, Position Subject : Microbiology 1973 PhD, University of Western Ontario Canada, Subject: Immunology Thesis Titles 1968. M.Sc. Thesis: Cross reactions of avian and mammalian gamma globulins, Karachi University, Pakistan 1973. PhD Thesis: Isolation, purification and characterization of an Ascaris suum allergen, University of Western Ontario, Canada. PROFESSIONAL QUALIFICATIONS 1989 : MRC Path: London, U.K. Subject: Immunology 1997 : FRC Path: London, U.K. Subject: Immunology. BRIEF CHRONOLOGY OF EMPLOYMENT 1968-69 Assistant Lecturer, Department of Microbiology, University of Karachi, Karachi, Pakistan 1970-72 Teaching Assistant, Department of Bacteriology and Immunology University of Western Ontario, Canada 1973-75 Research Associate, National Research Council (USA) Naval Medical Research Institute, National Naval Medical Center. 1976-79 Instructor, Department of Medicine, John Hopkins University, USA 1979-81 Collaborative Researcher, National Institutes of Health, National Institutes of Allergy and Infectious Diseases. USA 1981-85 Senior Staff Fellow, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA. 1985-90 Associate Professor, Department of Microbiology The Aga Khan University, Karachi, Pakistan Jan - March 2005 2 Acting Chairperson, -
CMAJ WHO Enters New Terrain in Ebola Research
CMAJ News WHO enters new terrain in Ebola research he meeting on unproven inter- ventions for Ebola at the World T Health Organization on Sept. 4 and 5 takes the global agency into “absolutely uncharted territory,” says WHO spokesperson, Dr. Margaret Harris. “We’re actually often criticized for being incredibly slow about saying, ‘Do this over that’, because we demand enormous levels of evidence,” she says. But for Ebola virus disease, there are no approved therapies, so WHO is attempting to move investigational interventions forward, including medi- cations, vaccines and so-called conva- lescent serum, made from the blood of survivors. The Sept. 4 meeting, aimed at guid- ing research in the midst of the out- NikiLitov/iStock/Thinkstock break, marks a sharp turn for WHO, In the absence of approved therapies for patients diagnosed with Ebola, WHO is taking where research efforts are viewed as the unprecedented step of attempting to move research forward. fragmented. About five years ago, WHO eliminated its office of research break at 78%, and in late August the three control animals died. Five of the strategy; the department leading the disease spread to another country — seven people treated with ZMapp have Ebola research effort, known as Senegal — and another city — Port survived, but it is unclear if the medica- Knowledge, Ethics and Research, was Harcourt, Nigeria, the hub of Nigeria’s tion helped them to recover and it will only formed at the end of 2013. But the oil and gas industry, where Canadian be months before there is more ZMapp Ebola crisis forced a change. -
Keynote Speakers
Keynote Speakers Dr. Katie Flanagan, BA(Hons) MBBS DTM&H MA PhD CCST FRCP FRACP, leads the Infectious Diseases Service at Launceston General Hospital in Tasmania, and is a clinical Associate Professor at the University of Tasmania, Australia. She obtained a degree in Physiological Sciences from Oxford University, followed by her MBBS from the University of London. She is a UK and Australia accredited Infectious Diseases Physician. Katie obtained her PhD in malaria immunology based at Oxford University. She was previously Head of Infant Immunology Research at the MRC Laboratories in The Gambia from 2005-11. Dr. Thumbi Ndung’u, BVM, PhD, is the Scientific Director of the HIV Pathogenesis Programme at the University of KwaZulu Natal in South Africa. He is a virologist with a PhD from Harvard University, Boston, USA. His main research interests are in host-virus interactions and immune responses in HIV-1 infection. He is also interested in the development of biomedical interventions that can be used in resource-limited settings to prevent or treat HIV/AIDS. He is an Associate Professor in HIV/AIDS Research at the the Doris Duke Medical Research Institute, Nelson R Mandela School of Medicine, University of KwaZulu-Natal. He holds the South African Department of Science and Technology/National Research Foundation (DST/NRF) Research Chair in Systems Biology of HIV/AIDS. Dr. Josef Penninger BA, MD, PhD, is Scientific Director of the Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Vienna, Austria. He is Professor in the Departments of Immunology and Medical Biophysics at the University of Toronto, Canada, Professor of Genetics, University of Vienna, Austria, Honorary Professor of Peking Union Medical College/Chinese Academy of Medical Sciences, Beijing, China, Affiliate Scientist, Keenan Research Centre, Li Ka Shing Knowledge Institute of St. -
The Dynamic Changes in Cytokine Responses in COVID-19
meeting report SARS-COV-2 The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge “The role of cytokines in COVID-19” online symposium was presented on 18 June 2020 by the NIH/FDA Immunology and Cytokine Interest Groups and was purposed to discuss our rapidly changing understanding of COVID-19-related cytokine responses in diferent stages of infection, including the etiologies, downstream consequences and possible mitigation strategies. The recording is available at https://nci.rev.vbrick.com/ sharevideo/03106730-66cc-47ba-870b-f6e6274a998a. he symposium was opened by address that underscored the broad variety serum cytokine concentrations with disease Anthony Fauci, Director of the of clinical presentations of COVID-19, outcome. Her data showed that IL-6, IL-8 TNational Institute of Allergy and thus highlighting the central role of the and TNF, and to a lesser extent, IL-1β, were Infectious Diseases at the US National immune response in this disease. She also elevated at the time of hospitalization, and Institutes of Health (NIAID, NIH), and remarked on the apparent geographic their concentrations correlated with disease Janet Woodcock, Director of the Center clusters of disease manifestations and the outcome and mortality, even after correcting of Drug Evaluation and Research, Food need to better understand possible factors for age, ethnicity, race and comorbidities, and Drug Administration (CDER, FDA) in host–pathogen interactions beyond those suggesting that they could be used to and currently leading the therapeutics health conditions already identified, such identify patients at risk of severe disease2. component of Operation Warp Speed.